NCT05094336 2026-03-31
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT06178445 2026-03-27
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05771480 2026-03-25
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT03875235 2026-03-19
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT05994001 2026-02-18
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Shanghai Zhongshan Hospital
Phase 1/2 Active not recruiting
NCT04005339 2026-01-26
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
Phase 2 Active not recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT05036486 2026-01-20
The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer
National Health Research Institutes, Taiwan
Active not recruiting
NCT05170438 2026-01-20
LenPac
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT06084481 2026-01-20
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
Phase 1 Active not recruiting